PREDICTORS OF PATIENT REPORTED MEDICATION ADHERENCE TO ANTIRETROVIRAL THERAPY by Cerimagic, Zlata
University of Rhode Island 
DigitalCommons@URI 
Open Access Master's Theses 
2001 
PREDICTORS OF PATIENT REPORTED MEDICATION ADHERENCE 
TO ANTIRETROVIRAL THERAPY 
Zlata Cerimagic 
University of Rhode Island 
Follow this and additional works at: https://digitalcommons.uri.edu/theses 
Recommended Citation 
Cerimagic, Zlata, "PREDICTORS OF PATIENT REPORTED MEDICATION ADHERENCE TO ANTIRETROVIRAL 
THERAPY" (2001). Open Access Master's Theses. Paper 239. 
https://digitalcommons.uri.edu/theses/239 
This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion 
in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, 
please contact digitalcommons@etal.uri.edu. 
( 
( 
MEDICATION ADHERENCE IN HIV POPULATION 
BY 
ZLATA CERIMAGIC 
.. 
A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE 
REQUIREMENTS FOR THE DEGREE OF 
MASTER OF SCIENCE 
IN 
PHARMACY ADMINISTRATION 
UNIVERSITY OF RHODE ISLAND 
2001 
( 
( 
PREDICTORS OF PATIENT REPORTED MEDICATION ADHERENCE TO 
ANTIRETROVIRALTHERAPY 
BY 
ZLATA CERIMAGIC 
A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE 
REQUIREMENTS FOR THE DEGREE OF 
MASTER OF SCIENCE 
IN 
PHARMACY ADMINISTRATION 
UNIVERSITY OF RHODE ISLAND 
2001 
( 
MASTER OF SCIENCE THESIS 
OF 
ZLA TA CERIMAGIC 
APPROVED: 
( Thesis Committee 
Major professor l.A..r-z;C/~/ JV~7 
~~~--
UNIVERSITY OF RHODE ISLAND 
2001 
ABSTRACT 
The acquired immunodeficiency syndrome (AIDS) caused by human immuno 
deficiency virus (HIV) is still a significant public health problem. In the 
United States approximately 1,000,000 people live with HIV/AIDS infection.4The 
recommended treatment is HAART (highly active antiretroviral therapy) . The HAART 
treatment is very complex, because of a large number of prescribed drugs in a regimen, 
frequent dosing and also a number of side effects. In HIV management precise 
adherence13• 26 to the prescribed medication regimen is the key for the maximal viral 
suppression and improved health status, and the only way to turn this deadly disease 
into a manageable chronic disease. The importance of many factors associated with 
medication adherence, including patient characteristics, disease characteristics, 
medication regimen characteristics, and the patient-provider relationship has been 
documented. One of the aspects of the complexity of the prescribed regimen is the 
number of medications in the regimen. 
Results: The number of medications did not show association with medication 
adherence. Patients on a more complex antiretroviral medication regimen did not miss 
higher percent of prescribed medication, and we may not discriminate between 
adherent and non-adherent patients only based on a number of prescribed antiretroviral 
medication. Also the variables number of side effects and how long ago HIV positive 
were negatively associated with medication adherence. 
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INTRODUCTION 
Epidemiology of HIV I AIDS infection 
The acquired immunodeficiency syndrome (AIDS) caused by human 
immunodeficiency virus (HN) is still a significant public health problem. From 1981 , 
which marked the beginning of the HIV pandemic, throughout the following 20 years, 
HIV/AIDS has spread worldwide affecting every single country. 1 Epidemiological 
picture of HIV I AIDS infection around the world for the last year has the following 
indicators; more than 5 million new cases of HIV infection had occurred in 2000. 
Estimated prevalence tells that currently around the world about 36 million people live 
with HIV I AIDS infection. The WHO also has reported that AIDS caused 22 million 
deaths .2 In the United States approximately 1,000,000 people live with HIV/AIDS 
infection.3 The incidence of HIV infection is about 40,000 cases each year.3 In this 
country more than 420,000 people have already died from AIDS.4 
Adherence-key factor in HIV/AIDS treatment 
Current therapeutic options for HNI AIDS patients include more than 15 antiretroviral 
drugs, commonly grouped in the three classes as: nucleoside reverse transciptase 
inhibitors (NRTD, nonnucleoside reverse transcriptase inhibitors (NNRTD and 
protease inhibitors (PI). 5'6'7'8 From 1996 the highly active antiretroviral therapy 
(HAAR T) has been used as a standard of care for symptomatic as well asymptomatic 
HN positive patients. 5•9•10 The HAART treatment is very complex, because of a large 
number of prescribed drugs in a regimen and frequent dosing.9•10 Also a number of 
( 
side effects, drug interactions, toxicities and also very specific food restrictions make 
this treatment not only complex but also very demanding for the patients and 
consequently difficult for lifetime precise adherence.5•9•10•11 •12•13•14 Previous research 
suggests that in general patients with more complex medication regimen are less 
adherent to the prescribed regimen. 12' 15•16 In contrast, several other studies reported 
increased medication adherence with an increase in a number of prescribed medication 
in a regimen.17•18•19 Several studies did not find an association between medication 
regimens' complexity and patient medication adherence.20•21 Because previous 
research reported uncertain and inconclusive findings; there has been a need for more 
research on adherence and medication regimen complexity in HIV population. Clear 
understanding of this issue is necessary, and may have important implications for 
further treatment of HIV positive patients, as well as further incentive for 
pharmaceutical industries. 
Adherence to a prescribed medication regrmen reqmres taking medication as 
prescribed consistently.22 Adherence or compliance was defined by Fisher as 'a 
concept used to measure'23 positive patients' behavior 'in meeting their therapeutic 
goals. '23 In HIV management precise adherence 7'9' 12' 24 to the prescribed antiretroviral 
medication regimen is the key for the maximal viral suppression and improved health 
status, longer and better quality of life, and the only way to turn this deadly disease 
into a manageable chronic disease.7' 12'22 '24'25 Poor medication adherence and irregular 
use of prescribed antiretroviral medication with inadequate drug concentration may 
result in resistance and consequently reduced treatment options for HIV positive 
2 
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patients. 8•12' 13•22•26 Although research did not define how frequently an HIV positive 
patient can miss antiretroviral medication before resistance develops less than optimal 
results were reported with medication adherence lower than 90%. 9•25•34 In addition 
because HIV resistant strains might be transferred to others, poor medication 
adherence in HIV/AIDS management may have a devastating impact on a public 
health. 16•22 •24•25•27 Thus, strict adherence to the prescribed antiretroviral medication 
regimen is essential and estimation of factors associated with medication adherence in 
HN population present a crucial issue in HIV management and current research. 
Previous research has reported different medication adherence rates in the HIV 
population. Wenger et al. reported 57% adherence to prescribed medication regimen 
19
, Willey et al. reported 86% adherence,29 and Samet et al. reported 67% adherence30. 
Poor adherence to the prescribed antiretroviral medication regimen of 60% and 42% 
were reported by Eldred JL, et al. 31 and Muma et al. 32 
Medication non-adherence also causes higher costs of HIV I AIDS treatment because of 
increased number of complications and development of opportunistic infections, 
hospitalizations, and finally increased mortality of the HIV infected patients. 13 
Consequences of medication non-adherence are the most obvious in HIV population. 
Hogg et al. reported that for every 10% decrease in adherence, the mortality rate 
increases by 16%. 33 Few studies have reported direct relationships between the level 
of patients' adherence to a prescribed antiretroviral therapy and viral load suppressions 
as well as CD4 cell count status. 10• 25•34 
3 
( 
Factors associates with adherence: 
Previous research has reported a number of different factors associated with 
adherence to the prescribed medication regimen. 15'22 '35 Adherence is a very complex 
phenomenon, and may be influenced by many different factors. These factors are 
commonly grouped as: 
• Patient characteristics 
• Disease characteristics 
• Medication regimen characteristics 
• Patient-provider relationship characteristics 12' 15 
A. Patient characteristics: include age, gender, race, employment, occupation, 
income, health insurance, living arrangements, marital status, number of children, and 
social support. 15 Not all patients' characteristics influence medication adherence in 
the same way. Demographics do not seem to have predictive value for medication 
dh 1 h h h h b . d . b f d" 12 14 17 19 20 22 a erence, a t oug t ey ave een examme m a num er o stu ies. ' ' ' ' ' 
Older age, gender, race, income or employment has been reported to influence 
dh b . 1 d fi d" 11 . 1 . 14 15 16 a erence ut not consistent y, an m mgs are genera y mconc us1ve. ' ' 
Recently a few studies have found that low literacy contributes to poor medication 
adherence. 52' 53 Patient characteristics, most frequently reported to positively 
"nfl d. . dh . 1 d . I fr f: ·1 d fr . d 12 22 30 i uence me icat10n a erence, me u e socia support om am1 y an ien s. ' ' 
Also optimism and trust in prescribed antiretroviral treatment, and belief in successful 
outcomes as well as knowledge about antiretroviral medication, and knowledge about 
4 
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the importance of strict adherence in the treatment with antiretroviral medication lead 
b dh ·bd d. · · 12303 1 39 H bh . . to etter a erence to prescn e me icat10n regnnen. ' ' ' uman e av1or is very 
complex and a number of psychosocial factors has a significant influence on 
medication adherence. A number of studies have found that psychological problems, 
lifestyle such as homelessness, alcoholism or drug abuse, contribute to medication 
non-adherence. 16, 19,20,2 1,22,24,29,30,34 
B. Disease characteristics: include symptoms, duration, diagnosis, number of 
hospitalizations, severity, and extent of disability. 15 Disease characteristics such as 
lack of symptoms or long term treatment usually influence medication adherence 
negatively. 15 Previous studies have reported poor medication adherence in both 
long-term treatments as well as short-term treatments with an average of fifty-percent 
adherence. 15'36 Even poorer medication adherence rates are common in preventive 
treatment or treatment of asymptomatic patients.36'37 Certain diagnoses such as 
psychiatric illnesses, depression, and mental disorders are commonly associated 
with problems oflow medication adherence.16'24'38 The literahrre regarding other 
disease characteristics and medication adherence is inconclusive. 
C. Medication regimen characteristics: include number of medications, type of 
medication, side effects, number of doses, duration and cost. 15 Many studies reported 
decreased medication adherence as the regimen became more complex and the number 
of prescribed medications increased.12' 15 ' 16'37'39 Several studies found quite the 
opposite, increased adherence as the number of prescribed medications increased. 
5 
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I 7 18 I 9 30 Q h h d . . 11 . . fi . . 
' ' ' t er researc ers reporte stahstlca y non-s1gru icant or mcons1stent 
associations between number of prescribed medications and medication adherence. 
2021404142s1 Th f d. · · fl dh 11 d. · 
' ' ' ' ' e type o me icat10n may m uence a erence as we as me icahon 
class. 16'18'21'39'40 Treatments with a number of side effects were reported as a cause of 
poor adherence to the prescribed medication regimen.12'16·43 Dosage frequency 
influences adherence negatively; as the number of prescribed doses increases, 
adherence to the prescribed medication regimen is reported to decrease. 12·18' 21· 
40,42,44,4S 
D. Patient-Provider relationship characteristics: have been evaluated in a number 
f d. IS24314042 46p "bl h . f; h . fl . o stu ies. ' ' ' ' ' oss1 y t e most important actor t at m uences patient 
medication adherence is the patient physician relationship.22'37'46 Friendly, respectful, 
and long-term relationships between a patient and his/her physician is a very important 
part of the success of both the therapy and patient adherence.ss The physician should 
provide patients with detailed information about the disease and medication, and 
provide written information about antiretroviral medication use. Physicians ' 
knowledge and experience in the treatment of HIV positive patients may generate 
higher patient trust and confidence and positively influence adherence.12'47 Other 
healthcare providers such as nurses or pharmacist's, who provide clear explanations 
about treatment options may also influence patients medication adherence positively as 
well. 
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Methods of adherence measurement: 
In a search for the best and the most accurate measure of medication adherence 
researchers develop a number of different methods. Commonly these methods are 
grouped as direct or indirect. Directly we measure medication adherence by 
monitoring medication use by patients, and by testing blood and urine for the presence 
of drugs, metabolite, or drug markers. 15'38'48'49 The disadvantage of these methods is 
that they do not give information about Jong-term medication use behavior28. Although 
direct methods probably have a higher sensitivity and specificity than indirect 
methods, they are more expensive and more inconvenient for the patients.49 Indirect 
methods include pill counts, physician assessment, and self-reported adherence to a 
prescribed medication regimen, prescription refill records, and electronic monitoring. 
11 ,12,15 ,38,48,49 
A. The pill count method is based on the count of returned pills. This method was 
very frequently in use in older research literature. The major disadvantage of this 
method is unreliability. Because patients may not return all unused pills, this method 
may be misleading and result in overestimated adherence. 
B. Physician assessment provides inaccurate estimates of patient adherence, and with 
this method the adherence rate is generally overestimated. 38•48•49 
C. The self-report method includes questionnaires, diaries, and patients' interviews. 
21
•
46 Questionnaires are often used in research because they are relatively simple and 
fast way to collect data about small or large populations. Some researchers consider 
patients' self-report as accurate measure of patient adherence, and others believe that 
7 
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self-reported data overestimates adherence.25'33' 48 '50 A self-report is more convenient 
for the patients, and less expensive than other measures.24 With cooperative patients, 
who are willing to disclose their behavior, self-report has the potential to be an 
accurate measure of patient adherence.24 
D. The prescription refill records method is based on the use of pharmacy records, 
and gives unique opportunity to explore adherence usually in a larger population, and 
usually over longer periods of time. The disadvantage of this method is that we know 
that prescription was filled, but we do not know did actually patient use the medication 
as prescribed. 
E. Electronic monitors are method based on use of the computerized drug containers. 
Electronic monitors provide data with dates as well as time intervals of each opening 
of the bottle. Electronic monitors use may also overestimate the adherence rate 
because we know that bottle was opened but we do not know whether the prescribed 
medication was used.48 They are also expensive and impractical for large populations 
as well as multi-drug regimens. For some forms of medication electronic monitors 
cannot be used. Also because of awareness that their behavior is monitored patients 
may be more adherent. Because there is no gold standard perhaps the most accurate 
estimate of medication adherence may be obtained by using several methods in the 
same study, which also gives an opportunity for reliability and validity comparison 
between the measures. 11 '36' 48 
8 
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STATEMENT OF PURPOSE 
A review of the literature shows the importance of precise and strict adherence to 
complex antiretroviral regimens in the HN population. The importance of many 
factors associated with adherence, including patient characteristics, disease 
characteristics, medication regimen characteristics, and the patient-provider 
relationship characteristics have been documented. The primary objective of this study 
is to analyze and estimate the point prevalence of HN positive patients' adherence to 
complex antiretroviral medication regimens and to examine the association of the 
following factors with adherence: 
• Medication regimen complexity as a predictor of medication adherence while 
controlling for patient characteristics, disease characteristics, and medication 
regimen characteristics. 
The secondary objective is to explore other potential predictors of medication 
adherence. The hypothesis is that a number of medications may influence patients' 
medication adherence. Patients on a more complex multi-drug regimen very likely will 
be less adherent to the prescribed medication regimen than patients on a less complex 
drug regimen. The patients on a more complex antiretroviral regimen, including a 
larger number of prescribed medications very likely will miss more doses of 
prescribed medication and demonstrate the poorer adherence to the prescribed 
antiretroviral medication regimen. 
9 
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METHODOLOGY 
Study Design 
This is a descriptive, cross-sectional study of self-reported medication adherence to 
prescribed HIV related medication regimen. 
Study Sample 
The study sample consists of 145 participants, all diagnosed as HIV positive patients. 
A patients' eligibility to participate in this study was 1) over 18 years of age, 2) ability 
to read and write English, and 3) currently using an antiretroviral medication, or 
medication for HIV related complications. The study sample was not random sample. 
All study participants were patients attending clinics. For participation, each person 
received $20. 
Data Collection 
Data was collected in Rhode Island and Massachusetts at the Miriam Hospital 
Immunology Center, the Stanley Street Treatment Center, and the Veterans Affairs 
Medical Center. The physicians from each clinical site asked HIV positive patients for 
consent to participate in the study. All data was collected by a self-reported 
questionnaire. Questionnaires were distributed to most patients at the clinic, with the 
option to complete the questionnaire at the clinic or at home and to bring it or mail it 
back. Fifteen study participants, (10.34%) were incarcerated and questionnaires were 
delivered to them in prison. A research assistant was available at both sites to respond 
to any questions regarding the self-administered questionnaires, and with the pictures 
and names of all HIV- related medications. HIV positive patients filled out the self-
10 
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reported questionnaire during the year 1996-1997 (see appendix). From the six 
sections of the questionnaire titled 'Managing Your Medication Questionnaire' only 
section I 'Background Information' and section II 'Medication History' were used in 
the analysis, (Willey, Unpublished data). 
Measures: 
The questionnaire collected information about the following: 
A. Patients' characteristics: age, gender, health status, race, education, employment, 
living arrangements, number of people in household, number of children, adult 
children nearby, emotional support from family and friends, financial support from 
family and friends, physical assistance and place to stay, number of people that you 
have told about HIV infection, health insurance, income, and distance from treatment 
center, anyone to reminds about medications, mood status and coping skills (attitude 
toward antiretroviral medication). 
B. Disease characteristics: bodily pain in the past 4 weeks, pain interference with 
work in the past 4 weeks, days in bed in the past 2 weeks, number of hospitalizations 
in the past year, how long ago diagnosed, how got HIV infection, CD4 cell count last 
tested. 
C. Medication regimen characteristics: number of medications, medication class, 
how often use medications, how long on medication, drug holidays or discontinuation 
of prescribed medication for more than 3 days, number of side effects, number of 
doses missed in the past week, number of doses missed in the past month, number of 
11 
( 
doses missed in the past three months. Questions about the number of doses missed 
were asked in a nonjudgmental manner. Participants were asked questions such as: 
"Sometimes it is difficult to take prescribed medicine all the time. During the past 
month, about how many times did you miss a dose of medication 1 ?" The same 
question was asked for each drug in a patients' regimen. HN positive patients were 
asked about the number of doses missed in the previous week, as well as the previous 
month, and the previous three months. 
D. Patient-Provider relationship characteristics: the most helpful health care 
provider, and questions about medication use. 
Method 
The total number of prescribed HN related medications was calculated for each 
participant; a larger number of prescribed medications corresponds to a more complex 
regimen. The participants of this study were considered absolutely adherent (100%) to 
prescribed antiretroviral therapy if they did not report missing any doses of prescribed 
regimen in the previous month. Dependent variable medication adherence was 
calculated using the following formula: {(total# of doses prescribed I total# of 
medication) - (total #of doses missed) I total# medication)} I (total# of doses 
prescribed I total# of medication)* 100. Consequently, a higher percent of doses 
missed in the past month correspond to a higher level of medication non-adherence. 
With multiple ANOV As the participants who reported 100% adherence were 
separated as a sample and were used for comparison with the non-adherent sample. 
12 
Statistical Analvsis: 
Data was analyzed using Multiple Regression Analysis with SAS program (Statistical 
Analysis Software), Version 8.0. The computer facilities and the library at the 
University of Rhode Island was used for the data analysis as well as for the all 
necessary research work. Data were checked for the accuracy of the data entry and for 
the basic assumptions of linearity, normality, and homoscedasticity. SAS procedures 
proc mean and proc plot were used to check for outliers and linearity assumption of 
all. Collinearity and singularity was checked also. The dependent variable, self-
reported medication adherence (percent of doses taken), in the past month was used in 
analysis because of the least skewness and kurtosis compared to self-reported 
medication adherence in the past week or self-reported adherence in the past three 
months. Also one month was considered as better time period for the evaluation of 
medication taking behavior compared to one-week period. Recall bias was less likely 
in a period of a month compared to three months period. Because of severe non-
normal distribution logarithmic transformation was performed on the dependent 
variable medication adherence. Variables were considered significant predictors for 
the p-value below 0.05. If independent variables were categorical then independent 
variables were dummy coded. 
The Questionnaire was designed to ask about the number of doses missed in the 
previous month for each medication in patients ' regimen; from the first drug in the 
regimen to the sixth drug in a regimen. But the questionnaire was not designed to ask 
about the number of doses missed for the regimen of 7 or more drugs. Seven study 
13 
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participants, (5%) were on the regimen of 7 or 8 drugs. Because most study 
participants, (71 %) were on regimen of four or less than four drugs they did not 
respond on the questions about the number of doses missed in the previous month for 
the fifth or sixth drug in a regimen. Because information on the number of doses 
missed in the previous month was missing for approximately 80% of variables for the 
fifth or sixth drug in the regimen was not used in the analysis. This is illustrated in 
Table 1. In accordance with this all computations were performed for the regimen of 
four or less than four drugs. The variables to be evaluated included: 
Dependent variable: 
Two dependent variables were created. The first dependent variable medication 
adherence was calculated for all study participants using the following formula: 
A. Medication adherence, (percent of doses taken in the previous month): 
0-100% (continuous), was defined and calculated as: 
{(total # of doses prescribed I total # of medication) - (total # of doses missed) I total 
# medication)} I (total # of doses prescribed I total # of medication) * 100. 
Medication adherence was calculated for the regimen of four or less than four drugs in 
the regimen. 
The second dependent variable was calculated only for the study participants who 
reported that they had missed their medication. Consequently study participants who 
reported that they never missed their medication were not included. Medication 
adherence was defined and calculated as: 
14 
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B. Medication adherence, (percent of doses taken in the previous month): 
0 - 99% (continuous), was defined and calculated as: 
{(total #of doses prescribed I total# of medication) - (total #of doses missed) I total 
# medication)} I (total # of doses prescribed I total # of medication) * 100. 
Medication adherence was calculated for the regimen of four or less than four drugs in 
the regimen. 
Independent variables: 
A. Independent variables grouped as Patient Characteristics: 
• Age (continuous) 
• Race (categorical) 
1 - Non-White 
0 - White 
• Education (continuous) 
• Annual Income (categorical) 
1 - <$ 24,000 
0 - > $25,000 
• Employment (categorical) 
1 - Full-time/Part-time 
0 - Not employed 
• Health Status (categorical) 
1 - ExcN g/Good 
15 
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0 - Fair/Poor 
• Number of family and friends that you can count on for physical assistance or 
place to stay. (continuous). 
B. Independent variables grouped as Disease characteristics 
• Bodily pain in the past 4 weeks (ordinal) 
1 - None (Very mild/Mild/Moderate) 
0 - Pain (/SevereN ery Severe) 
• Number of hospitalizations in the past year (continuous) 
• Days in bed in a last 2 weeks (continuous) 
• CD4 cell count last tested (categorical) 
1 - Greater than 500 
0 - Less than 500 
• How long ago diagnosed HIV positive (categorical). 
1- >l year 
0- <l year 
C. Independent variables grouped as Medication regimen characteristics 
• Total number of prescribed medication (continuous); 1- 4 
SumofQillX+QII2X+Qil3X+Qil4X 
• How long on HIV related medication (categorical) 
1 - <=l year 
0 ->l year 
• Number of side effects (continuous) 
16 
Sum of A: nausea, B: dizziness, C: vomiting, D: abdominal pain, E: diarrhea, 
F: shortness of breath, G: muscle aches, H: fatigue, I: tingling in hands/feet, 
J: numbness in hands/feet, K: headaches, L: anxiety/worry, M: depression, N: rash, 
0: sensitivity to sun. 
Preliminarily multiple regression analyses were performed, on each separate group of 
factors most likely associated with adherence to prescribed medication regimen. 
Multiple regression analyses were performed for: predictors ' group patient 
characteristics, predictors group disease characteristics, and predictors group 
medication regimen characteristics. Stepwise Multiple Regression analysis including 
the factors most highly associated with medication adherence from each group, as well 
as all other factors was carried out to define the best fit for the final model. 
• Multiple regression analysis model for the dependent variable Medication 
Adherence(% of doses taken, 0 -100%) vs. the independent variable group: 
patient characteristics. 
Medication Adherence = Age +Race + Education + Employement + Health Status 
+ Annual Income+# of People for Physical Assistance/Place to stay. 
• Multiple regression analysis model for the dependent variable Medication 
Adherence(% of doses taken, 0- 99%) vs. the independent variable group: 
patient characteristics. 
Medication Adherence = Age + Race + Education + Employement + Health Status 
+ Annual Income +# of People for Physical Assistance/Place to stay. 
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• Multiple regression analysis model for the dependent variable Medication 
Adherence(% of doses taken, 0 -100%) vs. the independent variable group: 
disease characteristics predictors. 
Medication Adherence = Pain during past 4 weeks +Number of hospitalizations 
+ Days in bed + How long ago diagnosed + CD4 cell count. 
• Multiple regression analysis model for the dependent variable Medication 
Adherence(% of doses taken, 0- 99%) vs. the independent variable group: 
disease characteristics predictors. 
Medication Adherence = Pain during past 4 weeks+ Number of hospitalizations 
+ Days in bed + How long ago diagnosed + CD4 cell count. 
• Multiple regression analysis model for the dependent variable Medication 
Adherence(% of doses taken, 0-100%) vs. the independent variable group: 
medication regimen characteristics. 
Medication Adherence = Total nun1ber of medications + Number of side effects 
+ Duration of medication use. 
• Multiple regression analysis model for the dependent variable Medication 
Adherence(% of doses taken, 0- 99%) vs. the independent variable group: 
medication regimen characteristics. 
Medication Adherence = Total number of medications + Number of side effects 
+ Duration of medication use. 
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• Stepwise Multiple Regression Analysis model for the dependent variable 
Medication Adherence(% of doses taken, 0 -100%) vs. the independent 
variables grouped in the final model. 
Medication Adherence =Total number of medications +Number of side effects 
+ Health insurance +Number of Children + How long ago diagnosed as HN positive. 
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RESULTS 
A: Patient Characteristics 
Detailed demographics of this study population are given in Table 2. The mean age of 
the study population was 39 ± SD 7; (range 24-57 years). The study sample was 
predominantly White, (63%). A majority of the study participants (71 %) were males. 
A high school education or less was reported by 67% of the study population. A 
majority of the study participants were not currently employed; 72% reported that they 
do not work. 59% reported an annual income of less than $15,000. A significant 
number, (82%) reported lack of health insurance. In general, this study sample 
reported a high level of social support. About 60% of the sample reported feeling very 
or fairly confident that family or friends would continue to help with everyday needs. 
About 95% of the study participants reported that they have told all or most of their 
friends or relatives about their HIV status Living arrangements that include partners, 
spouses, other adults, parents, or their children were reported by 70% of the study 
sample. Approximately half of the sample reported that they have children. Also about 
50% of the study participants reported that they have somebody who lives close to 
them to remind them about the use of the prescribed medications. 39% reported belief 
that they got HIV through IV drug use; the rest reported homosexual or heterosexual 
contact as a transmission risk. 
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B: Disease characteristics 
In general, a majority of the sample population, (73%) reported excellent, very good, 
or good health status. Also 63% reported that they had never been hospitalized. Only 
13% of study participants reported severe or very severe bodily pain. Almost half, 
46%, confirm that they never feel so weak that they need to spend a day in a bed. The 
majority, 63%, reported long duration of disease; they had been diagnosed 5 years or 
longer ago. In this study population basically 43% had developed AIDS, because 13% 
reported a CD4 cell count less than 50, and 30% reported a CD4 cell count between 50 
and 200. Table 3 shows the frequency of indicators of health status. 
C: Medication regimen characteristics 
The mean number of prescribed medications was 3.7 drugs. Prescribed HIV related 
medications regimen range from monotherapy to 8 drugs therapy. 6 study participants, 
or 4%, were on monotherapy, 30 study participants, or 21 % were on 2-drug therapy, 
and 41, or 28%, were on 3-drug therapy. 24 study participants or 17% were on a more 
complex regimen of 4 drugs. 44 study participants or 30% were on a regimen of 5 and 
more drugs. Antiviral medications were prescribed for almost all study participants 
(99%); 50% had protease inhibitors in their regimen, and 56% additionally used 
antinfective medication for HIV related complications. The most commonly prescribed 
antiviral medications in this study population were: lamivudine or epivir (3TC), 
prescribed for 121 patient or 83%; then stavudine or zerit (D4T), prescribed for 69 
patients or 49%; and zidovudine or retrovir (AZT), prescribed for 65 participants or 
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45%. Among antiinfectives, bactrirn or septra (Trimethoprirn) was the most commonly 
prescribed drug, for 67 patients or 46%. Among protease inhibitors, the most 
commonly prescribed drug was Indinavir (Crixivan), prescribed for 58 participants or 
40%. The most common frequency of dosing was two or three times a day for each 
drug in a regimen. The prescribed regimens did not cause any side effects in 26% of 
study population. The rest confirm that they experienced from one to a number of side 
effects. Table 4 shows the frequency of indicators of medication regimen. 
D: Patient-Provider relationship characteristics 
Physicians were described as the most helpful health care providers. If study 
participants have questions about their medications, 91 % ask their physicians, 31 % ask 
a pharmacist, and 30% a nurse. Patient provider relationship characteristics are shown 
in Table 5. 
E: Medication adherence 
Almost half of the study sample reported that they had never missed a dose of 
prescribed medication. There appears to be a significant difference in reported strict, 
100% adherence. 70% of study participants reported 100% medication adherence in 
the past week for the first drug in a regimen. However, only 46% HIV positive patients 
reported 100% adherence with prescribed medication in the past month, and 41 % of 
study participants reported 100% medication adherence in the past three months. A 
summary of this information is presented in table 6. 
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In this sample about one half (48%) of study participants reported medication non-
adherence. They reported that they had missed from 1 to 35 doses of prescribed HIV 
related medication in the previous month. Table 6A present percent of those who 
reported non-adherence, (1-35 doses missed), as well as percent of those who reported 
strict adherence, (0 doses missed), and percent of missing data. 
A significant number of study participants, reported unintentional non-adherence29 ; 
46% reported forgetfulness as a reason for missing a dose of prescribed medication. 
Also a high number reported intentional non-adherence29 ; 25% reported sometimes 
being careless about taking prescribed antiretroviral medication regimen. 19% admit 
that sometimes they stop the use of prescribed medication. 14% reported drug holidays 
for 3 or more days. 
The mean number of prescribed doses missed in the previous month was 5 doses. Self-
reported mean medication adherence in the previous month was high and was 
calculated to be 97%, with a minimum of 58% and maximum of 100%. The mean 
medication adherence in the past week was 95%, and the mean medication adherence 
in the past three months was 98%. 
F: Multiple Regression Analvsis and Stepwise multiple Regression Analysis 
Multiple regression analyses were performed for the following models: predictors' 
group patient characteristics, predictors' group disease characteristics, predictors' 
group medication regimen characteristics and Stepwise multiple regression analysis for 
the final model. 
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Table 7: The result of multiple regression analysis for the dependent variable, 
Medication Adherence(% of doses taken, 0- 99%) Vs. the independent variables 
group patient characteristics: 
The model was significant F7, 67 = 2.71 (Pr> F 0.0154), and R2 = 0.2208. This suggest 
that 22.08% of the variability in the dependent variable may be explained by the 
model. The result of the multiple regression analysis showed that race (Non-White) 
and education had significant positive association with medication adherence. Other 
variables such as age, employment, annual income, health status, and number of 
people available for physical assistance did not show significance at the 0.05 level. 
Table 7 A: The result of multiple regression analysis for the dependent variable, 
Medication Adherence(% of doses taken, 0-100%) vs. the independent 
variables group patient characteristics: 
The model was not significant F7, 122 = 1.72 (Pr> 0.1103), and R2 = 0.0898. This 
suggest that 8.98% of the variability in the dependent variable may be explained by the 
model. The result of the multiple regression analysis showed that race had significant 
association with medication adherence. Other variables such as age, employment, 
education, annual income, health status, and number of people available for physical 
assistance did not show significance at the 0.05 level. 
Table 8: The result of multiple regression analysis for the dependent variable, 
Medication Adherence (% of doses taken, 0 - 99%) vs. the independent variables 
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Group disease characteristics predictors: 
The model was not significant F5, 70 = 0.27 (Pr >0.9273) and R2 = 0.0190. None of the 
predictor variables such as number of days in bed, pain interference with work, bodily 
pain, how long diagnosed as HIV positive or CD4 cell count showed significant 
relationship with dependent variable medication adherence. 
Table SA: The result of multiple regression analysis for the dependent variable, 
Medication Adherence(% of doses taken, 0-100%) vs. the independent 
variables group disease characteristics predictors: 
The model was not significant f 5,128 = 0.72 (Pr > 0.6122) and R2 = 0.0272. None of the 
predictor variables such as number of days in bed, number of hospitalizations, bodily 
pain, how long diagnosed as HIV positive or CD4 cell count showed significant 
relationship with dependent variable medication adherence. 
Table 9: The result of Multiple regression analysis for the dependent variable, 
Medication Adherence(% of doses taken, 0- 99%) vs. the independent variables 
group medication regimen characteristics: 
The model was not significant F4, 75 = 1.89 (Pr > 0.1386) and R2 = 0.0703 . None of the 
variables grouped as medication regimen characteristics, including number of 
medications, number of side effects, or duration of treatment, showed significant 
association with dependent variable medication adherence. 
Table 9A: The result of Multiple regression analysis for the dependent variable, 
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Medication Adherence(% of doses taken, 0-100%) vs. the independent 
variables group medication regimen characteristics: 
The model was not significant F4,134 = 2.24 (Pr > 0.0867) and R2 = 0.0477. The 
variable side effect showed statistically significant association with dependent variable 
medication adherence in contrast to the variables number of medications, or duration 
of treatment. 
Table 10: The result of Stepwise Multiple Regression Analysis for the final model 
for dependent variable Medication Adherence(% of doses taken, 0 -100%) vs. 
the independent variables grouped in the final model: 
The final model was significant F5,134 = 3.44 (Pr> 0.0059). In this model R2 = 0.1138 
suggesting that 11.38% of the variability in dependent variable medication adherence 
may be predicted by the model. The variable number of side effects and number of 
children showed negative statistically significant association with the variable 
medication adherence. The variable total number of medication did not show 
significant association with medication adherence; p-value was non-significant, 
0.0921. Other variables in the model such as How long ago diagnosed as HIV positive, 
and Health insurance also did not show statistically significant association with 
medication adherence in the final model. 
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Table 1: Percent of HIV Positive Patients Who Responded 
On the Questions About the # of Doses Missed 
Medication # Past week Past month Past 3 months 
Medication #1 97.93% 94.48% 90.34% 
missing data 2.07% 5.52% 9.66% 
Medication #2 91.03% 87.59% .. ,. 86.21% 
missing data 8.97% 12.41 % 13.79% 
Medication #3 68.97% 69.66% 68.28% 
missing_ data 31 .03% 30.34% 31.72% 
Medication #4 34.97% 34.97% 33.57% 
missing data 65.03% 65.03% 66.43% 
Medication #5 20.28% 19.58% 19.58% 
missing data 79.72% 80.42% 80.42% 
Medication #6 10.49% 10.49% 10.49% 
missing data 89.51% 89.51% 89.51% 
*Past Week(% who responded about# of doses missed/past w.) 
*Past Month(% who responded about# of doses missed/past m.) 
*Past 3 Months (% who responded about# of doses missed/past 3 m. 
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Table 2: Patient Characteristics 
Age (mean ) 39 +/- 7 
Gender Participants # Participants% 
Female 42 29% 
Male 102 71% 
Race Participants # Participants% 
White 91 63% 
African-American 23 •:16% 
Hispanic 16 11% 
Native American 4 3% 
Other 10 7% 
Education Participants # Participants % 
< 12 years 48 33% 
12 years 46 32% 
> 12 years 51 35% 
Employment Participants # Participants % 
Not employed 105 72% 
Full-time 22 15% 
Part-time 17 12% 
Health Insurance Participants # Participants % 
No Health Insurance 119 82% 
Health Insurance 23 16% 
Annual Income Participants # Participants % 
< 15,000 85 59% 
15,000-24,000 26 18% 
25,000-34,000 9 6% 
35,000-44,000 12 8% 
> 45,000 4 3% 
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Table 2: Patient Characteristics cont. 
Living Arrangement Participants # Participants% 
With Others 101 70% 
Alone 44 30% 
#Children Participants # Participants % 
No 66 46% 
Yes 79 54% 
Social Support Participants # Participants % 
Very or fairly confident in suppor 88 61% 
Somewhat confident 24 17% 
Less than somewhat or not at al 29 20% 
Got HIV Infection Participants # Participants % 
IV Drug use 57 39% 
Homosexual 51 35% 
Heterosexual 46 32% 
Blood Transfusion 4 3% 
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Table 3: Disease Characteristics 
Health Status Participants# Participants % 
Excellent 11 8% 
Very Good 33 23% 
Good 62 43% 
Fair 33 23% 
Poor 6 4% 
Bodily Pain Participants # Participants % 
None 37 26% 
Very mild 28 19% 
Mild 19 13% 
Moderate 42 29% 
Severe 14 10% 
Very severe 5 3% 
Days in Bed Participants # Participants % 
0 67 46% 
1-20 74 51% 
Number of Hospitalizations Participants # Participants % 
0 92 63% 
1-8 51 35% 
Disease Duration Participants # Participants % 
Less than a month 1 1% 
One to six months 4 3% 
> 6 months but < 1 year 4 3% 
1-2 years 14 10% 
3-4 years 27 19% 
5 years or more 92 63% 
CD4 cell count Participants # Participants % 
> 500 20 14% 
201-500 53 37% 
50-200 44 30% 
>50 19 13% 
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Table 4: Medication regimen characteristics 
Total number of med. (mean) 3.7 
# of prescribed medication Participants# Participants % 
1 (monotherapy) 6 4% 
2 30 21% 
3 41 28% 
4 24 17% 
5 25 17% 
6 12 
-
8% 
7 6 4% 
8 1 1% 
Medication Class Participants # Participants % 
Antivirals 143 99% 
Protease Inhibitors 73 50% 
Antiinfectives 82 57% 
Most freq. prescribed drugs Participants # Participants % 
Epivir (3TC) 121 83% 
Stavudine (D4T) 69 48% 
Trimethoprim (Bactrim) 67 46% 
Zidovudine (AZT) 65 45% 
lndinavir (Crixivan) 58 40% 
How long taking medication Participants # Participants % 
Less than 1 month to 6 months 49 34% 
6 months to 1 year 26 18% 
1 to 2 years 26 18% 
more than 2 years 42 29% 
Freq. of medication use Participants # Participants % 
2X per day 80 55% 
3X per day 40 28% 
# of Side effects Participants # Participants % 
0 (none) 38 26% 
1 - 5 46 32% 
6 - 10 40 19% 
> 10 34 24% 
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Table 5: Patient - Provider Characteristics 
Questions about Medications Participants # Participants % 
Physician 132 91% 
Pharmacist 45 31% 
Nurse 43 30% 
Other HIV person 39 .. 27% 
Most Helpful Health Care Prov. Participants# Participants% 
Physician 65 45% 
Nurse 27 19% 
Pharmacist 19 13% 
Other 14 10% 
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Table 6: Self-Reported 100°/o Adherence rates in the HIV population 
Mean Adherence for Medication #1 
Past Week 69.66% 
Past Month 46.21% 
Past three months 41.38% 
Medication #1 (first drug in a regimen) 
Medication #2 (second drug in a regimen) 
Medication #3 (third drug in a regimen) 
Medication #4 (fourth drug in a regimen) 
Medication #2 Medication #3 Medication #4 
60.69% 51.03% 31.47% 
46.21% 42.07% 25.87% 
42.07% 35.86% 22.38% 
*Past Week (self reported 0 doses missed (100% adherence) in the past week) 
*Past Month (self reported 0 doses missed (100% adherence) in the past month) 
*Past 3 Months (self reported 0 doses missed (100% adherence) in the past 3 months) 
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Table 6A: Percent of those who reported 0 or >=1 doses missed 
#Doses Missed Medication #1 Medication #2 Medication #3 
Past Month (0 doses) 56.25% 
Past Month (>=1 doses) 43.48% 
Medication #1 (first drug in a regimen) 
Medication #2 (second drug in a regimen) 
Medication #3 (third drug in a regimen) 
Medication #4 (fourth drug in a regimen) 
56.52% 
43.48% 
*Past Month (self reported 0 doses missed in the past month) 
*Past Month (self reported >=1 doses missed in the past month) 
60.87% 
39.13% 
Medication #4 
71.11% 
28.89% 
TABLE 7 A: Multiple regression analysis model for the dependent variable 
Medication Adherence(% of doses taken, 0 - 100%) vs. the independent variable 
group: patient characteristics 
INDEPENDENT STANDARD STANDARD P-value 
VARIABLES COEFFICIENT ERROR 
AGE 
_(continuoutl 0.00016 0.00037 0.6769 
#YRS. EDUCATION 
(continuous) 0.00147 0.00113 0.1937 
#PHYSIC. ASSIST. 
(continuous) -0.00036 0.00062 0.5640 
RACE 
_{_cate_g_orica!l 0.01958 0.00638 0.0027 
EMPLOYMENT 
_(cate_g_orica!l 0.01069 0.00650 0.1022 
ANNUAL INCOME 
J cat~orica!}_ -0.00084 0.00789 0.9157 
HEALTH STATUS 
(categorical) -0.00762 0.00674 0.2610 
R2 = 0.0898 
F1,122 = 1.72 (Pr> F 0.1103) 
Dummy coding as 1 ' s and O' s were performed on every categorical variable used 
in analysis. 
AGE (continuous) 24- 57. 
EDUCATION (continuous) 3 - 20. 
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#OF PEOPLE FOR PHYSIC. ASSIST./PLACE TO STAY (continuous) 0-30. 
RACE was coded as: 
1- Non-White 
0- White 
EMPLOYEMENT was coded as: 
1- Full/Part-time Employed 
0- Not Employed. 
ANNUAL INCOME was coded as: 
1- <24,000 
0- >25,000. 
HEALTH STATUS was coded as: 
1- ExcNG/Good 
0- Fair/Poor. 
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TABLE 7: Multiple regression analysis model for the dependent variable 
Medication Adherence(% of doses taken, 0 - 99%) vs. the independent variable 
group: patient characteristics 
INDEPENDENT STANDARD STANDARD P-value 
VARIABLES COEFFICIENT ERROR 
AGE 
(continuous) 0.00027 0.00055 0.6268 
#YRS. EDUCATION 
(continuous) 0.00354 0.00173 0.0444 
#PHYSICAL 
ASSISTANCE. -0.00109 0.00086 0.2111 
_(continuous) 
RACE 
J_cat~orica!}_ 0.04083 0.01030 0.0002 
EMPLOYMENT 
(categorical) 0.02019 0.01150 0.0836 
ANNUAL INCOME 
_{_cat~orica!} 0.00044 0.01200 0.9705 
HEAL TH STATUS 
__{_ cat~orica!l -0.01745 0.01081 0.1114 
R2 = 0.2208 
F 1,61 = 2.71 (Pr> F 0.0154) 
Dummy coding as 1 ' s and O' s were performed on every categorical variable used 
in analysis. 
AGE (continuous) 24 - 57. 
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EDUCATION (continuous) 3 - 20. 
#OF PEOPLE FOR PHYSIC. ASSIST./PLACE TO STAY (continuous) 0-30. 
RACE was coded as: 
1- Non-White 
0- White 
EMPLOYEMENTwas coded as: 
1- Full/Part-time Employed 
0- Not Employed. 
ANNUAL INCOME was coded as: 
1- <24,000 
0- >25,000. 
HEALTH STATUS was coded as: 
1- ExcNG/Good 
0- Fair/Poor. 
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TABLE 8A:Multiple regression analysis model for the dependent variable 
Medication Adherence(% of doses taken, 0 - 100%) vs. the independent variable 
group:Disease characteristics predictors 
INDEPENDENT STANDARD STANDARD P-value 
VARIABLES COEFFICIENT ERROR 
#DAYSINBED 
_{_continuou~ -0.00008 0.00099 0.9359 
HOW LONG AGO 
DIAGNOSED _{_cate_g_orical) -0.00767 0.00945 0.4188 
BODILY PAIN _icate_g_orica!)_ 0.00428 0.00638 0.5035 
P AINI INTERF. With 
WORK _icate_g_orica!l_ -0.00173 0.00831 0.8356 
CD4 CELL COUNT 
_icate_g_orica!)_ 0.01219 0.00756 0.1094 
R2 = 0.0260 
Fs,12s = 0.68 (Pr> F 0.6377) 
Dummy coding as 1 's and O's were performed on every categorical variables used 
in analysis. 
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DAYS IN BED (continuous) 0 - 20. 
HOW LONG AGO DIAGNOSED (categorical) was coded as: 
0- >1 year 
0- < 1 year 
BODILY PAIN was coded as: 
1- No Pain (None, Very Mild, Mild) 
0- Pain (Moderate, Severe, Very Severe) 
PAIN/INTERFERENCE WITH WORK was coded as: 
1-No interf. (Not at all, A little bit, Moderately) 
0- Yes interf. (Quite a bit, Extremely) 
CD4 CELL COUNT was coded as: 
1- > 500 
0- < 500. 
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TABLE 8:Multiple regression analysis model for the dependent variable 
Medication Adherence(% of doses taken, 0 - 99%) vs. the independent variable 
group:Disease characteristics predictors 
INDEPENDENT STANDARD STANDARD P-value 
VARIABLES COEFFICIENT ERROR 
#DAYSINBED 
_(_continuous}_ -0.00053 0.00151 0.7273 
HOW LONG AGO 
DIAGNOSED J_cat~orica!l_ 0.00557 0.01993 0.7806 
BODILY PAIN _{_cate_g_orical} 0.00327 0.00901 0.7180 
# HOSPITALIZATIONS 
_{_continuous}_ -0.00042 0.00038 0.2770 
CD4 CELL COUNT 
J_cat~gorica!}_ -0.00128 0.00884 0.8850 
R2 = 0.0190 
Fs,10= 0.27 (Pr> F 0.9273) 
Dummy coding as 1 's and O's were performed on every categorical variables used 
in analysis. 
DAYS IN BED (continuous) 0 - 20. 
HOW LONG AGO DIAGNOSED (categorical) was coded as: 
0- >1 year 
0- < 1 year 
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BODILY PAIN was coded as: 
1-No Pain (None, Very Mild, Mild) 
0- Pain (Moderate, Severe, Very Severe) 
NUMBER OF HOSPITALIZATIONS (continuous) 
CD4 CELL COUNT was coded as: 
1- > 500 
0- < 500. 
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TABLE 9A:Multiple regression analysis model for the dependent variable 
Medication Adherence(% of doses taken, 0-100%) vs. the independent variable 
group: Medication regimen characteristics 
INDEPENDENT STANDARD STANDARD P-value 
VARIABLES COEFFICIENT ERROR 
TOTAL# of MEDICATION 
_(continuous}_ 0.00351 0.00291 0.2294 
#OF SIDE EFFECTS 
(continuous) -0.00074 0.00030 0.0133 
HOW LONG ON MED. 
( cate_g_orical) 0.00026 0.00513 0.9591 
R2 = 0.0477 
F 3, t34 = 2.24 (Pr > F 0.0867) 
Dummy coding as 1 's and O's were performed on every categorical variable used 
in analysis. 
TOTAL# OF MEDICATION (continuous); 1 - 4. 
TOTAL NUMBER OF SIDE EFFECTS (continuous); 0- 45. 
HOW LONG ON MEDICATION was coded as: 
0- <=1 year 
0- >1 year 
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TABLE 9:Multiple regression analysis model for the dependent variable 
Medication Adherence (% of doses taken, 0 - 99%) vs. the independent variable 
group: Medication regimen characteristics 
INDEPENDENT STANDARD STANDARD P-value 
VARIABLES COEFFICIENT ERROR 
TOTAL# of MEDICATION 
J_continuou~ 0.00417 0.00446 0.3525 
# OF SIDE EFFECTS 
(continuou~ -0.00111 0.00049 0.0275 
HOW LONG ON MED. 
J_cate_g_orical) -0.00559 0.00804 0.4895 
R2 = 0.0703 
F 3,1s = 1.89 (Pr > F 0.1386) 
Dummy coding as 1 's and O's were performed on every categorical variable used 
in analysis. 
TOTAL# OF MEDICATION (continuous); 1 - 4. 
TOTAL NUMBER OF SIDE EFFECTS (continuous); 0- 45. 
HOW LONG ON MEDICATION was coded as: 
0- <=1 year 
0- >1 year 
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TABLE 10: Stepwise Multiple Regression analysis for the dependent variable 
Medication Adherence(% of doses taken, 0 - 100%) vs. the independent 
variables. 
Inde_I!_endent Variables R-S_g_uare F-value P-value 
# of Medication 
Ste.£_ 0 J_continuou~ 0.0071 0.081 0.3696 
# of Side Effects 
Ste_Ql J_continuou~ 0.0403 3.87 0.0516 
Health Insurance 
Ste.£_ 2 
_il=no O~e~ 0.0724 3.85 0.0524 
# of Children 
Ste.£_3 J_continuou~ 0.0937 2.58 0.1109 
How long HIV+ 
St~4 J_l>=l _year 0<1 _y_earl 0.1195 3.19 0.0767 
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TABLE lOA: Final model for Multiple regression analysis for the dependent 
variable Medication Adherence (% of doses taken, 0 - 100%) vs. the 
independent variables. 
Independent Standard Standard P-value 
Variables Coefficient Error 
# of Medication 
J.continuous}_ 0.00406 0.00239 0.0921 
# of Side Effects 
_icontinuous}_ -0.00075 0.00025 0.0035* 
How long HIV+ 
_il>=l _year 0<1 _yeaij_ -0.01244 0.00764 0.1049 
# of Children 
J. continuous}_ -0.00021 0.00011 0.0464* 
Health Insurance 
_il =no O=_y_es}_ 0.00886 0.00552 0.1104 
R 2 = 0.1138 
Fs,134 = 3.44 (Pr> 0.0059) 
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DISCUSSION 
The medication regimen prescribed for HIV I AIDS patients is described in the research 
literature as complex and demanding, and consequently difficult for lifetime strict 
adherence. Adherence to a complex medication regimen is a challenge for patients, 
and requires patients' motivation and devotion to treatment. Non-adherence is 
considered by some authors to be a behavioral problem. For a patient to stay adherent 
to a complex, probably lifelong, antiretroviral treatment "requires change in patient 
behavior"29· Non-adherence in HIV management is a major obstacle to improved 
health status. 
It is difficult to define a real degree of non-adherence in the study sample because we 
do not have precise and accurate methods to measure patients' adherence to prescribed 
medication regimen. Multiple regression analyses as well as Stepwise multiple 
regression analysis was carried out on the total sample as well as on the smaller sub-
s"cunple of the study participants who reported missing medication. This method did 
not help to define more potential predictors of medication adherence. 
When adherent study participants were compared with multiple ANOVA's to non-
adherent study participants, they were similar. No significant differences were found 
between the two groups, although the non-adherent sample had slightly more women, 
more hospitalizations, longer duration of disease, and worse CD4 cell count. 
Adherence was high in this study population. Perhaps, adherence rates were 
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overestimated, or this population was highly motivated, and, with high social support, 
they were adherent to the prescribed medication regimen. 
A: Patient Characteristics 
Potential predictors of medication adherence grouped as patient characteristics 
include: age, education, race, employement, annual income, health status, and number 
of people for physical assistance or place to stay. Model for the total sample was not 
significant. Model which include sub-sample of non-adherent study participants, (0 
doses missed were deleted), was significant. Only variables, race (Non-White) and 
education showed positive association with medication adherence in this model. 
B: Disease characteristics and 
C: Medication regimen characteristics 
Predictors grouped as disease characteristics, and medication regimen characteristics 
did not show statistically significant association with variable medication adherence. 
D: Final model; Stepwise Multiple Regression Analysis 
Using Stepwise Multiple Regression Analysis the following variables were included in 
the final model: Total number of medication (continuous), Number of side effects 
(continuous), Number of children (continuous), Health insurance (categorical none vs. 
some) and How long ago diagnosed as HIV positive (categorical l>=l year vs.O<l 
year). 
Variables which did not enter the model included: age (continuous), race (categorical 
non-white vs. white), education (continuous), annual income (categorical <$24,000 vs. 
>$25,000), employment (categorical full/part-time vs. not employed), number of 
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family or friends for physical assistance or place to stay (continuous), bodily pain 
(categorical very mild/mild/moderate vs. severe/very severe), number of 
hospitalizations (continuous), days in bed in a last 2 weeks (continuous), CD4 cell 
count (categorical >=500 vs. <500), how long on HIV related medication (categorical 
>=l year vs. <l year). 
In the final model, unexpectedly, the number of medications did not show significant 
association with medication adherence. This finding is consistent with the previous 
research reported by Sing et al., 17 Baley et al.,21 Christensen et al., 40 and Sung et al.42 
For the better-fit variable total number of medication was transformed by squaring it, 
but the final result was almost the same as before transformation. Also results for the 
sub-sample was not significantly different from the results for the final model, 
including total sample. 
One of the aspects of the complexity of a prescribed regimen is the number of 
medications in a regimen, as well as the frequency of dosing, number of side effects, 
food requirements, taste, and cost. All this is true for the medication regimen 
prescribed for HIV I AIDS patients. This study findings suggest that more complex 
regimen, with larger nun1ber of medication does not necessarily lead to medication 
non-adherence. This is illustrated in Figures 1 and 2. Previous research also reported 
that it is most likely that it is not only the number of medication, but probably other 
aspects of the regimen complexity, such as the frequency of medication use, number of 
side effects, or perhaps nun1ber of psychological variables that contributes 
significantly to the patients medication non-adherence. 17 
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In the final model two variables showed negative statistically significant association 
with medication adherence: number of side effects and number of children. 
Previous research reported stable family situation as important and positive factor for 
patients' medication adherence, but association between the number of children and 
medication adherence was not reported. This study found negative association between 
number of children and medication adherence. Perhaps people with children had more 
duties including childcare and skip prescribed medication more frequently than people 
without children did. 
Number of side effects showed negative statistically significant association with 
medication adherence. The higher number of side effects in the regimen the less likely 
patients will adhere to such a regimen. This finding is consistent with the previous 
research. Catz et al. 57 and Proctor et al. 56 reported number and severity of side effects 
in the prescribed regimen as a significant predictor of patients' medication non-
adherence. Mehta et al. reported also that medication therapy with the number of side 
effects usually results in poor adherence to prescribed regimen. 16 
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CONCLUSION 
The results of this research project demonstrate that the number of prescribed 
antiretroviral medication may not predict patients' medication adherence. Patients on a 
more complex antiretroviral medication regimen did not miss higher percent of 
prescribed medication and we may not discriminate between adherent and non-
adherent patients only based on a number of prescribed antiretroviral medications. All 
this is consistent with previous research. Also variables number of side effects and 
number of children showed negative statistically significant association with 
medication adherence. 
The study has the following benefits: 
The advantages of a self-report, such as low cost, and fast and easy distribution, 
probably make it a good choice to study and collect data about larger as well as smaller 
populations. The relatively large study population, 145 patients, and the precise and 
nonjudgmental questioning gives researchers a unique opportunity to explore 
adherence issues in depth and to assess important and valuable information about 
adherence behavior as well as a nun1ber of other important factors associated with 
adherence in this population. Although the self-report is an indirect adherence 
measure, it has been reported by some authors as a measure with higher sensitivity and 
specificity over other measures. 25'35 A better understanding of adherence to a 
prescribed antiretroviral medication regimen in this HN population may help us to 
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develop intervention strategies, which would be valuable for this and other HIV 
patients, and a number of other chronic illnesses that require lifelong treatment. The 
results of this research will provide information about the patients' needs for health 
care providers as well as for pharmaceutical companies and manufacturers. 
The study has the following limitations: 
Because these are self-reported data estimate of the number of doses missed in the 
past month because of forgetfulness may not be exactly the number of doses missed. 
Some patients simply do not want to report non-adherence; recall bias and 
overestimation of adherence rate are real possibility in this type of data collection.22.24 
Although numerous methods for measuring adherence exist; no instrument satisfied all 
the necessary criteria to be accepted as gold standard to measure adherence rate. Data 
was collected during '96- '97, when combined therapies were being just introduced as 
a standard of care and at that time knowledge and infomrntion about the treatment 
options of HIV positive individuals was limited. However, the recommended standard 
of care is (HAART), a multiple drug therapy including potent protease inhibitors 
drugs, other than drug combinations used previously. Study sample size was a 
limitation for more in depth research about adherence rates in some subpopulation 
groups, such as incarcerated HIV positive participants, or HIV positive women. Study 
participants were mostly unemployed, without health insurance, and with long 
duration of disease. Race distributions were not typical for HIV population, and 
middle age White males were over sampled. Adherence was probably overestimated or 
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study participants were maybe more adherent to prescribed medication regimen than 
other, average HIV patients because they accepted to participate, and they already were 
patients in clinic. Because they were patients on the clinics maybe they received 
counseling about importance of medication adherence in HIV I AIDS management. 
Study design was limitation for an estimate of the prevalence of non-adherence over 
longer period of time. 
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I Managing Your Medications Questionnaire Please answer the following questions thoughifully and completely. This questionnaire is 
about how you tltink andfcel about the IiIV related medications that you are taking, ruul 
about the different strategies that people use to take their medications. It will take about 
45 minutes for you toji.ll tltis out. You mayfill it out at home and mail it in or you may 
return it to this clinic. When you turn it in, we will give you a gift certificate for $20 to 
tlmnk youfor yo1Lr parlicipcition. If you have tile time to fill it out here, you may turn it in 
to the person who _handed it to you, and receive your gift certificate now. 
CODE FOR THIS QUESTIONNAIRE: 
i\) Whal are lhe first:~ letters of your mother's firs! name? 
U} What is your birth date? 001001[]0 
nun dd yy 
SECTION I 
BACKGROUND INFORMATION 
The first sectton of this quesltonrwire asks about your background. 
..... Please circle or fill in lhe correct response for each question. 
1. \\Thal is your age? DO years 
2. What is your gender? M I' 
(1/1·3) 
(l/~ ·D) 
(l/10 -11) 
3. How would you describe your current health sl;:iius? (Please check onl' nnswer) (1/12) 
0 Excellent 0 Very Oood 0 Good 0 Fair 0 Poor 
4. Which of the fo!Lowmg best describes your etlm!c background? (L/13l 
0 Vlhlte. non-Hispanic 0 Hispanic 0 Afric-.in American 
0 Native American 0 A<;ian 0 OU1er' 
5. How many years of cducatio.n have you finished? OD t1n4-1r.1 
6. Do you currcnUy work either part-Ume or full lim1;:? 
0 l' ull-timc 0 Part-lime 0 Cam not currently employed 
7. Do you live by yourst'lf or with 0U1cr people? 
0 Dy myself 0 Wi1h others 
8. If you live with 0U1crs. how many (besides you} arc Jn your household? 00 
9. If you live with others. what ts their relationship lo you? (Check all tliaL appl!J) 
0 Husband or wife 0 Crandpnn::nts 
0 I nli mate parlner 0 Children 1mdc.r age l 8 
0 Other adults IS or older 0 Children over age 18 0 Parents 
Un1t.it"'1,o;11v1.tf llJ-..odt.• f-.frv'V'l, t::l9:1t1 
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(1/lG) 
(I/Iii 
{l/18--19) 
flno-2s1 
( 
10. Do you have any children? lfso. how many? (/jnonc, p11L 0) DD 
l l . Do any of your adult children live nearby [within a half ho'ir drive)? 
0 Yes 0 No D Nol applicabll: 
12. How many of your family or friends cru1 you count on for cmolional suppolt? DD 
13. How many or your family or friends can you count on for llnanclal help? DO 
14. How many or your fa~ or friends can you counl on for physical assistance, 
or a place to stay? OU 
15. Do you feel confident that your family or friends w!ll continue Lo hdp you with 
your everyday needs'? 
0 Vc1y confldcnt 
0 Fairly confident 
0 Somewhat confident 
0 Less than somewhat confident 
D No1 ;it all confident 
(1/27 ·2.R) 
(1/29) 
(1/:lO·:ll) 
(1/32-33) 
(1/3'1.:!5] 
(l/36) 
16. Tf you were to need more help with every day needs, do you feel confident that you.r family or 
friends could provide it? (l/37] 
0 Very confident 
0 Fairly confident 
0 Somewhat confident 
0 Less than somewhat confident 
0 Not at all confident 
17. !low many of your family & ftiends have you told abou l your HIV infection? 
0 None 0 Less U1an half 0 About half 0 More than half D All 
18. \Vhat type or health insurance coverage do you cmTcnUy have'? 
0 NONE 
0 Blue Cross 
0 Ocean State 
0 RIGHI\ 
0 HCHP 
0 Other private lnsurer 
0 HMO 
0 Medicaid 
0 Medicare 
0 Other 
19. Which of the following best estlmates your total (family) Income dunng U1e 
past 12 months? 
0 Less U1a.i1 $15,000 
0 $15.000 lo $2-1.000 
0 $25.000 to $31\,000 
0 $35,000 to $44.000 
0 45.000 or more 
20. About how far do you live from this treatment ci~nler? 
0 Within walking distance 
0 Within a Len minute drive or less 
0 Wit.hln a Lwenty minute drive or less 
0 Within a (b!rty minute drive 
O More than thirty minutes away 
64 
(1/381 
(1/3948) 
(1/491 
(l/00) 
( 
I 
2J. When you have questions :iboul medications for your HIV lnfectitm. who do you 
u s w11ly ask? (Please check all tliaJ. apJ)ly) (l/51·5Ul 
n Pharmacist D Ol.her persons with HIV infection 
0 Physician 0 Faml\y mcmbc:rs 
LJ SQCi<ll Worker 0 Friends 
0 Nurse 0 Other; pkasc spcclly _ (1/59·76! 
22. Which health c:arc provicter is most helpful to you in taking your medlcalions as d1n:clcd? tl/79) 
0 Nurse 
0 Pliannadsl. 
0 Physician 
0 Socin.I Worker 
0 Other; please specify 1211 201 
23. rs U1ere someone living with you or close lo you who helps or reminds you to take your 
met.licalions on time? (:l./21) 
0 Yes 0 No 
24. I fow much hodily pain have you had during lhe pasl four weeks? 12/22) 
0 None 0 Moderate 
0 Veiy mild 0 Severe 
0 Mild 0 Very Severe 
25. Durin!', lhe past 4 weeks. how much did pain interfere with your normal work (including both 
work outside Lhe hoine and housework)? l2/2:ll 
0 Nol al all 0 A little bit 0 Moderately D Quite a bit 0 Extr emely 
26. During lhe pasl two weeks. how many days <lid you stny in bed all or mos! 
of llie day? OD 12/24·25) 
27. How many times have you been hospitalized in lhe pas( year? (If none. put OJ 0 0 \2/26-27) 
28. These quest(ons are oJXJut how voufcc[ rutd how things have been. wWt tJO!l dw ing the past 4 
weeks. 
For ew:lt questfon. please give the one answer that comes closest to the WO.!J you have beenfeeling. 
How rnuclt of U1e lime clwi.ng the pas! 4 weeks ... 
NONE 
01'' TIIB 
TIMR 
ALITl'LS SOM£ 
nrr OF TUE 01' THE 
Tl~W. TIME 
AGOOO 
8fT OFTIIB 
TIME 
MOS1' 
OF THE 
TIME 
AU. 
OF THE 
= 
~l·'b1d vou ·ree1 rtiw~f.fp:~~·?.':I?"'-: ··-.·-- J'.~'F::K:::~o~~=-~~., o o ·G ". - ti 
b . Have you been a very ncivous O D 0 0 0 0 
person? 
:c. Have you. fetl'so'iluiv-r1:rn 1hi'? CJ '.'"":q,_~,:ra-- ·~~~G . .:r· ·;rn--::.. ~- tJ ;: o 
. ·.~~l7~u~4t?~~~~~~~-c,o:~t1;¥11e.:~~~~1~~~~~j5~;~-J~2 ;_i.·~c.·:~i. <· -: ~. . 
d. I lave you felt calm and peaceful? O O O O LJ 0 
W:iJ\d y0i1;i;r.y~<f,~tjt§t~D$E©~-~:::;.:f?J~li,,!fy~i·~i1El~~~~~o~ ' CJ :,~; ~er··· ;::;rm 
f. r-i ave you fell duwnhearled and O 0 0 -0 . . ·o .. --0 
blue? 
' g.' Did ;you .fc¢J:P9'?Nilµt~.~'f=;r... ·'":~~[] ·'>¥~?!EJ~;.-:/.!i G D .0 . '- .,_EJ . 
1i . i-1 ·;1~c you Geen a happ);re~on? .. 0 ···-· - ti · O O O O 
t. rnc1you reet :nrca? .. ··0i{}:";: :·~.'[] :' .;~~:,:D o ·o JJ 
Ut\fr\!rsl:y oj Wv:>dc ls.land C199? 
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(2/28) 
(2/2111 
(2/JO) 
(2/311 
(i/3'l) 
t2/J3J 
(2/:111 
{i/J!}J 
t2/ JGI 
( 
I 
29. How long ago were you diugnosed as mv positive? 
0 Less than a month 
0 One lo six months 
O More than six months. bul less Uwn a year 
30. How do you think you got your I-nv lnfeclion? 
Please check all thal apply 
0 Injection (IV) drug use 
0 Heterosexual cont.act 
0 Homose.'\.ual c:onlact 
0 Blood transfusion 
0 Other: 
0 l to 2 ye_ars 
0 3 to 4 years 
0 5 years or more 
3 I . What was your T cell count (CD4 counl) the last \.imc you were tested? 
0 Greater than 500 0 201-500 0 50-200 0 Less than 50 
Un.iv( .. ·r:slry of Wvxlc Isla.Ni. C!9<J6 
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12/:17) 
l</38 -41) 
[2/43-02) 
(2/63) 
I 
SECTION II 
MEDICATION HISTORY 
\VHICH OF Tl II.': FOi.LOWING MCDIC/fflONS ARE YOU TAl\.ING NOW? 
- PLEASE CI II~Cr< ALL '!1li\T :\.Pl'LY: 
0 AZT (Rclrovlr®, zidovudine) 
0 DOI (Vidcx®. <.it<.lanoslne) 
0 DOC (Hiv!d®. zalcllablne) 
0 D4T (Zeril(\SJ, stavu<.line) 
8 3TC (Epivir®, lamivudine) Saqulnavir (lnvfrase®) 
D Rilonavir (Norvir®) 
0 Oilier: 
---
0 lrn.linavlr (Crtxlvan®) 
0 Trlmcthoprim or Sulfamethox.'1zole (Baclriin®, Septrn.®J 0 Glartthromycin (Blaxin®) 
0 Dapsonc 
0 Ftuconazolc (Dillucan®) 
0 llr.tconazolc (SporanoA.'®) 
0 H.ifabuUn (Mycobutin®) 
We 'UH)uld like to ask you about each medicine that you are currenth1 taking. Please fill out 
the following 2 page medicationformfor each medicine that you checked on tfte above list. 
If you are currently taking 1 medication, Jill. out 2 pages. 
if yot1 are curren!.41 taking 2 medications. fill out 4 pages. 
+- If you are cw1ertLly taklng :~ medications, fill out 6 pages. 
if you are cwmrtUy taking more them 3 medications, pl.ease JW out 6 pages and addilional 
pages in the Supplement at the end of this questioMaire. 
Pease go to page 12 after you have filled out these medica.tfon fonns. , 
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MEDICATION #1 
MEDICINE NAM!!; ________________ _ 
r:111 201 
l. 11liS medicine Is for: (3/211 
n [l(V Infection 
0 To Lreut or prevent PCP (Pn.e11moc;1slis carinii pne11mornaJ 
0 To Lrcal or prevent fl.1Al (Mycobactcrium avlum complex) infccti<m 
0 To treat or prevent fungal tnfectlons (Calldida or "thrush") 
D OU1Cr: (3/?.2·4 IJ 0 Don't know 
2. I low often do you take this medicine? !J/42-f>ll) 
D 1\vo limes a week 
0 Three limes a week 
0 Every olher day 
0 011<:e a day 
0 'l\vo times a day 
0 Three times a day 
8 Four limes a day Five times a day 
0 Other: (:J/51-701 
3. Ilow long have you been laking Ulis medicalion? (J/71) 
Less than l monU1 __ 6 monUis to l year 
__ I lo 3 months __ 1 Lo 2 years 
4 lo 6 months __ more than 2 years 
4. During the [ast 3 month.s, have you ever stopped talang thls medication because you 
felt better? (3/721 
D Yl!:S D NO 
5. Duritlg the lgst .3 months. have you ever stopped laking lhls mecUcation be<-..ause you felt 
worse? 
0 YF'..S D NO 
6. During the last .3 months, have you ever ror~ottcn to take thls medication? 
0 YES D NO 
(3/?'JJ 
(3/71.) 
7. Dw-ing lite last 3 months, b.ave you at times been careless about taking Ulis medlr.alion? (3/"f?>J 
DYES 0 NO 
8. During lite last 3 months, have you ever taken less of thls medicine U1an your dodor 
prescribed because you felt better? (3/7GJ 
0 YES 0 NO 
9. Dttring the last 3 months. have you ever taken le§,'l of tl1ls medicine than your doctor 
prescribed because you felt worse? (3/77) 
0 YES D NO 
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10. §incc.you began laking this merliralion. have you ever purµoscly: 
a) ta ken more of the metl!clne than your physician prcscribt'd? 
bl taken less of lhe medicine than your physiciau prescribed? 
c) tliscoulinued or stopped taking your mcdir.aUon? 
.!Luefi. 
0 
0 
0 
NO 
0 
0 
0 
(3/71l) 
(3/7!1) 
(:1/!lO] 
l t. a) How many times have you discontinued your medication for more thaf) :-1 days'? (4/ 1 .. 2) 
b) What were yo1Jr reasons for dlsconUnulng your mcdicatlon? t~/3·lll 
(Plr:ase check all that apply} 
0 My doctor recommended it 
0 Too many side effects 
0 l didn't want to be reminded of my illness 
0 Problems with Insurance cover.:1ge 
D I didn 't think it was worlong 
D Other:---------- (t./9·28) 
12. Sometimes IL is difficult to take prescribed medicine all lhe lime. Durl.n1U .. fill ... m1st week, bow 
many times did you miss a dose of MEDICATION l? ___ (4/29-3oJ 
13. During the past month, about how many times did you miss a dose ofME:DlCATION i'? 
(4/31 32) 
14. Durin.g lhe past three months, about how many tlmes did you miss a dose MEDICATION 1? 
(4/33·3~) 
15. Please check any side e!Jecl(::>) you are having that you believe are caused by this mcdiclne: 
D nausea 
D dizziness 
D vomltlng 
D abdominal pain 
0 diarrhea 
D other: 
U11Jur .. •1·sity ~{ Uhc~!•_. f\lUt)(l ~l99(i 
0 shorlncss of breaU1 
D muscle aches 
0 faugue 
D tingling in hands/feet 
D ntunbness in hands/feet 
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l~/35 5-0J 
B
o headaches 
an,'l:iety /worry 
depression 
B rash sensili\ity to sun 
(4/51·70) 
( 
/ 
MEDICATION #2 
Ml::lJIC!NP: t\1\ME _________ ----
I. ·111i:; rnedielnc is for: 
rJ HlV infection 
8 To lrcal or prevent PCP (Pnewnocystis carirtff pneumonia) To Lreat or prevent MA.! (Mycobaclcrium avtum complex) lnfccUon 0 To treat or prevc.11l fungal infections (CaJtd.ida or "thrush") 0 Other: 0 Don't k_n_o_.w _____ _ 
2. How often do you take U11s medicine'? 
0 Two times a week 
0 ·ni.ree Limes a week 
D l::verv other day 
D Onc~aday 
0 Two limr~c; a day 
0 Three limes a day 
0 Four times a day 
0 Five limes a dav 
0 Other:----------
15/l 20) 
(5/211 
(5/22·4 I) 
lt>/42-50) 
15/51-70) 
3. I low long have you been taklng this medication? 15/71) 
. _Less lh.an l month __ 6 months to l year 
__ l rn :; rnonlhs __ I to 2 years 
4 to 6 monlhs __ more Uian 2 years 
4. During chc last 3 months, have you ever stopped laking this medication because you 
felt better? 15/721 
DYES D NO 
5. During U1e last 3 months, have you ever stopped laking thLs medlcalion because you felt 
worse? (5/731 
DYES 0 NO 
6. During the last 3 months. have you ever forgotten lo Lake Olis medicallon? 
D n:s D NO 
(5/74) 
7. Dw·ing the last 3 months, have you at times been rareless abou( taking this medication? (5/751 
DYES D NO 
8. During the last 3 mont~. have you ever taken less of Ulis medicine than your doclor 
prescribed bc<;ause you felt better? (S/7oJ 
0 YES D NO 
9. During the last 3 mont1ts, have you ever !iilken less of this medicine than your doctor 
prescribed because you felt worse? f5/77J 
0 Yr.S D NO 
l!111vcrstt11 '11<hod.e /'(Jmvl. f}J!J9G 
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10. Since ttou began takin</ U1is medication. have you ever purposely: 
YES 
a) w ken more of lhc medicine lhan your physi<'ian pr<'~<>cribcd? 0 
bl la ken les!; of lhe medicine llian your physician prescribed? 0 
c:) disconlinued or slopprd taki11~ your mcdicalion? D 
I[iws. 
NO 
0 
0 
D 
(5/78) 
(5/791 
(5/001 
11. a) How many times have you diseontlnued your mcdfcaUon for more than :i days? (6/ t-'.lJ 
bl What were your reasons for discontinuing your mcd!calion'? (6/3 SJ 
Please check all Lil.al appl!f 
D My doctor recommended il 
0 Too many side effects 
0 r didn'l wanl lo be reminded of my !llncss 
0 Problems wiU1 lnsurancc coverage 
0 I didn't lhlnk It was working 
0 OU1er: (6/0 211) 
12. Sometimes il is difficult lo lake prescribed medicine all the time. During the past week, bow 
many times did you miss a dose of Ml;:DICA110N 2? __ __ (G/29-301 
13. Durin.g the past month , about how many times did you miss a dose of MEDICATION 2? 
-··--- (6/ll..:12) 
14. During lhc past three months, about now many times did you miss a dose MEDICATION 2? 
(6/33-341 
15. Please check any side effer.t(sJ you are havl.ng thal you believe arc caused by lbis medicine: 
Onausea 
0dizziness 
Ovomlting 
O abdominal pai11 
Octtarrhea 
Oother: 
0 shortness of breath 
0 muscle aches 
0 fatigue 
D tingling in hands/ feet 
0 numbness ln hands/feel 
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(4/35 -50) 
0 headaches 
0 anxiety/wony 
0 depression 
, 0 rash 
0 sensitivity lo sun 
(G/Sl-70) 
( 
I 
MEDICATION #3 
MEDJCINE NAME, ________ ____ _ 
1. This 1111~ciicinc is for: 
0 HlV inrccllon 
0 To treal. 01· prevent PCP (Pneumocyslis carinii pneumonia) 
0 To treat or prevent MAI (Mycollactcrlurn avium complex} inlcclion 
0 To lreal or prevent fu ngal lnfccuons (Candida or "thrush") 0 OUit::r: ___ _ 
lJ Oon'l know 
2. llow often do you take llils mec1icine'? 
0 1\vo limes a week 
0 Three times a week 
0 C:very o~hc1· day 
0 Onct:a day 
0 Two times a day 
0 Three urnes a day 
0 Four limes a day 
0 ~·ive times a day 
0 Other: ·---------
(7/l-20) 
(7/2l) 
(7/22·4 l) 
(7/42·50) 
[7/51-70) 
3. How long have you been t.aking lliis medication? f7/7U 
_ _ Less lhan I month _ 6 months lo 1 year 
1 lo 3 months _ l to 2 years 
_ _ 4 lo 6 months __ more Uian 2 years 
4. During tile last 3 months, have you ever stopped lakini< lbis medlcalion because you 
fell better? (7/72) 
0 YES 0 NO 
5. During the last 3 months, have you ever stopocd taking this medication because you felt 
worse? {7/731 
0 YES 0 NO 
6. During IJie last 3 months, have you ever .fill:g9Jti>n to take this medication'? (7/74) 
DYES 0 NO 
7. During the last 3 months, have you al times bceu <.areless about taking this rnedlcauon'? (7/751 
0 YES 0 NO 
8. During the la.st 3 months, have you ever !aken less of th1s med!clnc than your doctor 
prescribed because you felt better? !7/'/61 
0 YF..S 0 NO 
9. During the last 3 months, have you ever taken kss of this medicine than your doctor 
prescriber! because you felt worse? '71771 
0 YES 0 NO 
lh1focrslty o{U,l11x.fr tdt.ulil, Ql996 
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HJ. Since uou began taking this medical!on. have you ever purposely: 
Y£S 
a) ta ken more of ll1c medicine than your physician prcscril}ed? 0 
bl l.akcn k:ss of l11c 1ncdlcinc than your ph}•slcian prescribed'? 0 
cl discontinued or slopped t;iking your medit:allon? 0 
li!JC§ .. 
NO 
0 
0 
0 
flf"/li) 
(7/791 
(7 /tlOI 
11. a) How many times have you disconlim1cd your mtdlcalion for more than 3 days? (H/111 
b) What were your reasons for dlsconU[luing your medicallon? 
Please check all lhat apply 
0 My doctor recommended lt 
0 Too many side effects 
0 I didn't want to be remirn.kd of my Illness 
0 Problems with insurance covenige 
0 I dldn't think it was working 
0 Other:-----------
[6/3·81 
(B/9·261 
12. Sometimes it is difficult to take prescribed medicine all the lime. Durin!! the past week, how 
many times did you mlss ;;i dose of !1.1EDICATION 3? _ _ _ (S/2.9-30) 
13. During the past month, about bow many times did you miss a dose of MED1CA'l10 3? 
tH/31 ·32) 
14. During the past three months, about how many times did you miss a dose M£DICA110N 3'? 
(8/33-341 
15. Please rheck any side effecl[s) you arc having 1.hat you believe arc caused by tills medicine: 
(6/35-501 
Onausea 
0dtzziness 
Ovomiting 
Oabdominal pain 
Octiarrhea 
Oothcr: 
D shortness of breaU1 
0 muscle aches 
Oratigue 
D tingling In hands/feel 
D numbness ln hands/feet 
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0 headaches 
0 anxiety/worry 
8 depression rnsh 
' 0 senslliv!ly to sun 
(6/51-70) 
/' 
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SUPPLEMENT TO SECTION II 
MEDICATION #4 
MEDICI NF: NAME ___________ ____ _ 
l. Th.ls medicine is for: 
0 HIV lnfectlon 
0 To treal or prevent PCP (Pneumocyslis carinii µneumoniaJ 0 To Lreat or prevent MAI (Mycobactertum avium complex) infection 
0 To treal or prevent fungal infections (Cundida or "thrush") 
0 Olhcr: ___ _ 
0 Don't know 
2. How often do you take this medicine? 
0 l\vo limes a week 
0 111ree times a week 
0 Every other day 
D Once a day 
0 1\vo limes a day 
D 111ree Limes a day 
D rOllf li mes a day 
D Five limes a day 
0 Olher: --- - -----
3. I low long have you been takin g this medication? 
l..e~s 1..han l monU1 
l to 3 months 
4 to 6months 
_ 6 months to l year 
_ l Lo 2ycars 
__ more than 2 years 
(15/36-55) 
ll5/SG) 
(1 5/57-?GJ 
(15/77) 
( 16/l 201 
4. Durtng the last 3 months, have you ever slopped taking this medication because you felt 
better? 001211 
DYES 0 NO 
5. During the last 3 months. have you ever stopped taking thls medication because you felt 
worse? (16/7.2) 
D YES 0 NO 
6. Duling lhe last 3 months. have you ever forgotten to take lhls mediC'alion? (16/23) 
0 YES 0 NO 
7. During the last 3 months. have you al limes been careless about taking lh!s medicaUon?11i;/24J 
0 YES 0 NO 
8. Du ring the last 3 months. have you ever taken less of this medicine than your doctor pre· 
scribed because you felt better? 1rn12s1 
D YES 0 NO 
9. During the last 3 months. have you ever taken less of this medicine than your doctor pre· 
scribed because you felt worse? (lu/2ul 
D YES 0 NO 
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JO. Since you bcczan taking lb.ls medication, have you ever purposely: 
YJ·:5 NO 
a) taken more of the medicine than your 
physlcla1L prescrib!'cl? 
b) taken less of Ute mcrhrine than your physician 
prescribed? 
cl discontinued or stopped lalung your medication? 
D D 
D D 
D D 
11 .a) I low many limes have you discontinued your medication for more 
than 3 days? 
b) What were your reasons for disronUnulng your medir;ition? 
Please check all l/1al. apply 
0 My doctor recommended It 
0 Too many side effects 
0 I didn't want to be reminded of my illness 
0 Problems with insurance coverage 
D I didn't think it was working 
0 Other:----------
(lti/UI 
(16/".!H) 
llG/29) 
(16/30-31) 
(16/32·37) 
(38 57] 
12. Sometimes it is difficult to take prescribed medicine all t.he. lime. During the past week, bow 
many times did you miss a dose of MEDLCATION 4? ___ 11s1sa-so1 
13. During U1e past month, abou t how many times did you miss a dose of MEDICATION 4? 
(tfi/GO GIJ 
14. During U1e past three months, about how many times did you miss a close MEDiCA'llON 4? 
(16/62-03) 
15. Please check any side cffect(s) you are having Uml you believe arc caused by this medicine: 
(16/64 ·~) 
0 nausea 
0 d1z7Jness 
0 vomiting 
0 abdominal pain 
D diarrhea 
0 other: 
l/nit'("r.di11 o/ flhock· lslwtf). tr:J9'J(i 
B
o shortness of brcalh 
muscle aches 
fatigue 
0 tingling In hands/feel 
0 numbness io hands/feel 
75 
0 headaches 
0 an.xlety /worry 
D depression 
0 rash 
0 sensitivity to sun 
(!7/1-20) 
( 
MEDICATION #5 
MlWIC!NE Ni\M~-----------------
I. This medici!1c is for: 
0 I IJV lnfecllon 
0 To lrcat or prevent PCP IPneumocysCi.s ca.rinii pnewnonta) 
0 To treat or prevent MAI (Mycobaclerium avlum complex) infeclion 
0 To treat or prevent fungal JnfecUons (Candida or "thrush") 
0 Other:------------0 Don't !mow 
2. How often do you take this medicine? 
0 'l\vo lime::; a week 
0 ·n1rce 1 imes a week 
0 Every olhcr day 
B Once a day 1Wo limes a day 0 Three \.imcs a day 
0 Four Limes a day 
0 Five Limes a day 
0 Other:---------
3. How long have you been taking this medJcalion? 
Less Uian I monlh 
__ I Lo 3 months 
__ 4 lo 6 months 
__ 6 months lo l year 
_I to2years 
_ more Umn 2 years 
117/~ I) 
(17/4~-61) 
[17/62) 
llfl/1·20i 
[16/21) 
1. DUiing the last 3 months, have you evc:r stopped taking this medical.ion b<:1:ausc you felt 
better? 11 a1221 
DYES D NO 
5. Duling lhe last 3 months. have you ever slopped Laking this 1uedication because you felt 
worse? llB/23) 
O ms D NO 
6. During the Last 3 mon t h.'>, have you ever forgotten to take this medicaUon? (18/24) 
D r'E:s D NO 
7. Oming lhe !ct.'>t 3 months. have you at times been careless aboul laking this medicalion'?oe12&1 
D YES D NO 
8. During I he last 3 months, have you ever taken less of lhi::; medicine than your doctor pre· 
scribed because you felt better? (lts/201 
D YF...S D NO 
9. Durtng the last 3 months. have you ever taken less of lhts mcclicine than your doctor pre-
scribed because you fell worse? (18/271 
DYES D f\O 
1Jnil.oc·r,.;,t111 of Uh.ock l:;ftpt1I, ~1~11.> 
76 
( 
Hl. S ince you beqan rnkin q this mcdieatlon. have you ever purposely: 
YF:S NO 
n) ta krn more or the mt:c.licine I han your 
phyi>ici;in prescribrd? 
b) lnken less of the medicine limn }'OUf µhysiciall 
prescribed? 
c) disconUnuetl or stopped Lale.Ing your mcrtiralion? 
0 
0 
0 
0 
0 
0 
~ 11.a) How many times have you 1.lisconUnucd your medit:alion for more 
lhan :; days? 
bl What were your reasons for dlsconlinuing your medication? 
Please dwck all that apply 
0 Mv doclor recommended ii 
0 Too many side effects 
0 I didn't wanl to be reminded of my illness 
B Problems wiU) insurance coverage r didn't think it was worlctng 
0 Other:------ ----
08/281 
(lB/291 
llll/30} 
ll8/3l·32) 
(IS/33·381 
(l6/39 58) 
12. Sometimes it is difficult lo lake prescribed medicine all the time. Du ring t he past week, how 
many times rlitl you nllss a dose of MEDICATION 5? __ __ !IS/59 ·601 
13. During the past month, about how many times did you mlss a dose ol'MEDICATION 5? 
(tB/Gl-021 
14. Duling the past three months, about how many times did you miss a dose Ml.W!CA110N 5? 
illi/63·64) 
15. Please check any side effeclls) you art> having lhal you believe are caused by this meditine: 
(18/G5-80l 
0 nausea 
0 clizziness 
0 vomlting 
0 abdominal pain 
0 diarrhea 
0 other: 
o
0
.. shortness of breath 
muscle aches 
0 fatigue 
0 tingling in hands/feel 
0 numbness in hands/feel 
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0 headaches 
0 an.'Ciety/worry 
0 depression 
0 rash 
0 sensltMly lll sun 
fll)/l -201 
( 
MEDICATION #6 
MEDICINE NAME_----------- ----- -
l. 'lhis mcclirine is for: 
0 mv infection 
D To treat or prevent PCP (Pneumocysti.s carinii pnewnonku 
0 To treat or prevent MAI (Mycobaclerium aviwn complex} iufcclion 
0 To !real or prevenL fungal infections (Candida or "lhrush") 
D OU1cr: ----·----- ----0 Don't know 
2. How oflen do you lake Lllis medlcinc? 
0 1\vo times a week 
D Three times a week 
0 Every 0U1er day 
D Once a day 
0 T\vo limes a day 
0 Three Umes a dt=1y 
0 Four limes a day 
0 Five times a day 
0 Othe.r: 
3. Ilow long have you been Laki1\~ Ulis medication? 
_ _ Less lhan 1 month _ _ 6 months lo l year 
__ 1 lo 3 months _ _ 1 to 2 years 
4 to 6 months _ _ more U1an 2 years 
(19/:zl 4ll) 
(19/•1 IJ 
( l9/12·6lJ 
(19/62) 
[20/ 1-20) 
(20/2 LJ 
4. During the last 3 months, have you ever s topped Laking lhis medication because you fell 
better? 1201221 
DYES D NO 
5. During U1c last 3 months, have you e\'Cr s topped taking lhls medication because you felt 
worse? (20/2:lJ 
DYES 0 NO 
6. During the last 3 months. have you ever forgoll.en lo take U1is medication? (20/24) 
D YES D NO 
7. During lh c last 3 months. have you at times been careless about taking this mcctienUon? t2012;;1 
D YES 0 NO 
8. During the last 3 mont hs. have you ever taken kss of (his medicine than your doctor pre-
scribed because you felt better? 120/26! 
D YP.: .. 'S D NO 
9. During lhc last 3 month.<>. have you ever lakcn less of this medicine lhan your doctor prc-
scrihed because you fell won;e? 1201211 
0 YES D NO 
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10. S ince 1LQ!l..J:w9an taking lliis mcdicalion. h3vr you ,•vcr puqJosdy: 
Yl~S 
al tak.:n more of the medicine Lhan yo\1r 
physician prescribed? 
b) tak<'n less of U1c medicine than your pl1ysician 
prescribed? 
cl disronUn11ed or stopped taking your mc<lication? 
0 
0 
0 
NO 
0 
0 
0 
+- 11 .l'I) How many limes have you cltsconUnucd your medlralilin for more 
than 3 days? 
bl What were your rc;isons for discomtnuln~ your medica llon? 
Please check all that apply 
0 My doctor recommended ll 
0 Too many side effects 0 l didn't wanl to be renundcd of my illness 
0 Problems with insurance coverage 
0 r didn't l.hlnk il was working 
0 Other: 
1·20/'lRJ 
(20/?9) 
\20/30) 
l?ll/3 l-321 
(2.0/33·~81 
12. Sometimes il is difficult to take pn·scribed medicine all lhc urnc. During the past week, how 
many times did you miss a dose of MEDICA"l10N 6? _ \21l/59·60J 
13. !)urlng the past month, about ltow ntany times did you m..lss a dose ofMt:DlCJ\TlON 6? (20/61-1$21 
14. During Lhe past three months, auoul ho w many times did you miss a dose MF:D!Cf\'110N 6? (~0/63·G-1l 
15. Please check any side effccl(s) you arc having thal you believe are caused by this medicine: 120/ti5-SOI 
0 nausea 0 dizziness 
OvomiUng 0 abdominal pain 
0 diarrhea 
0 olher: 
~ODO ~~:~~::~~l~~~rcalh 
Un~ling in hands/feel 
numbness in hands/feet 
--------
~-------
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0 headacncs 
0 amdcly/worry 
0 dt:prr_ssion 
0 rash 0 sensitivity to su n 
-------· 
12111-201 
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The SAS System 
11 :15 Monday, May 7, 2001 
Plot of COMP1MONTHL*QI1. Legend: A = obs, B = 2 obs, etc. 
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The SAS System 3 
11 :15 Monday, May 7, 2001 
Plot of COMP1MONTHL*HEALTH. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 100 obs had missing values. 
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11 :15 Monday, May 7, 2001 
Plot of COMP1MONTHL*race. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 100 obs had missing values. 
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Plot of COMP1MONTHL*QI5. Legend: A = 
COMP1MONTHL 
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11 :15 Monday, May 7, 2001 
obs, B = 2 obs, etc. 
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NOTE: 101 obs had missing values. 
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11 :15 Monday, May 7, 2001 
Plot of COMP1MONTHL*income. Legend: A = 1 obs, B = 2 obs, etc. 
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11 :15 Monday, May 7, 2001 
Plot of COMP1MONTHL*MEDTOTAL. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 132 obs had missing values. 
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Plot of COMP1MONTHL*SIDEEF. Legend: A= 1 obs, B = 2 obs, etc. 
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Plot of COMP1MONTHL*meduse. Legend: A = 1 obs, B = 2 obs, etc. 
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Plot of COMP1MONTHL*pain. Legend: A = 1 obs, B = 2 obs, etc. 
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Plot of COMP1MONTHL*cdcell. Legend: A = 1 obs, B = 2 obs, etc. 
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Plot of COMP1MONTHL*QI27. Legend: A= 1 obs, 8 = 2 obs, etc. 
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Plot of COMP1MONTHL*QI29. Legend: A= 1 obs, 8 = 2 obs, etc. 
COMP1MONTHL 
2.00 
1. 95 
1. 90 
1. 85 
1. 80 
1. 75 
8 
2 
A 
A 
A 
3 4 
HOW LONG AGO DIAGNOSED? 
NOTE: 100 obs had missing values . 
92 
F 
A 
A 
A 
5 
R 
E 
E 
A 
A 
A 
6 
The SAS System 8 
11 :15 Monday, May 7, 2001 
Plot of COMP1MONTHL*QI10. Legend: A = 1 obs, B = 2 obs, etc. 
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